Ovid Therapeutics (OVID) News Today

HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research note on Friday.

Shares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issue

Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,030,000 shares, a decline of 64.0% from the June 15th total of 2,860,000 shares. Currently, 1.8% of the company's shares are short sold. Based on an average daily volume of 830,100 shares, the short-interest ratio is currently 1.2 days.

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Analysts at HC Wainwright increased their Q2 2024 earnings per share estimates for Ovid Therapeutics in a note issued to investors on Tuesday, June 18th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Ovid Therapeutics in a report issued on Monday, June 17th. William Blair analyst T. Lugo now anticipates that the company will earn $0.12 per share for the

BTIG Research decreased their price objective on Ovid Therapeutics from $11.00 to $5.00 and set a "buy" rating for the company in a research report on Tuesday.

Oppenheimer downgraded Ovid Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday.

HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Ovid Therapeutics in a research report on Thursday.

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at Wedbush dropped their FY2024 EPS estimates for shares of Ovid Therapeutics in a report released on Tuesday, May 14th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.74) for the

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a note issued to investors on Tuesday, May 14th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.24) per share for the quarte

Shares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have give

Citigroup cut their target price on shares of Ovid Therapeutics from $4.00 to $3.50 and set a "neutral" rating on the stock in a research note on Tuesday.

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at B. Riley issued their Q1 2024 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, April 29th. B. Riley analyst K. Patel expects that the company will

FFT Wealth Management LLC acquired a new position in Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 395,774 shares of the company's stock, valued at approximately $1,274,000. FFT Wealth Management LLC ow

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Ovid Therapeutics in a research report issued on Monday, April 29th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.22) per share

B. Riley initiated coverage on shares of Ovid Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $9.00 price target on the stock.